Nortrel 1/35 21 Day: What Providers and Prescribers Need to Know in 2026

Patients prescribed Nortrel 1/35 21 Day (norethindrone 1 mg / ethinyl estradiol 0.035 mg, 21-day regimen) are increasingly reporting difficulty filling their prescriptions at retail pharmacies. While no national shortage has been declared as of 2026, a confluence of market factors creates real access barriers at the individual pharmacy level. This article provides a clinical overview of the issue and practical prescribing strategies to maintain uninterrupted contraceptive coverage for your patients.

Current Availability Status

Nortrel 1/35 21 Day is not on the FDA's current drug shortage list. The active pharmaceutical ingredients — norethindrone and ethinyl estradiol — are manufactured by multiple suppliers globally, and the overall national supply of norethindrone/EE 1/35 formulations is adequate. The access difficulties your patients are experiencing are primarily at the pharmacy level, driven by:

Generic market fragmentation: At least five therapeutically equivalent generics exist (Alyacen 1/35, Cyclafem 1/35, Dasetta 1/35, Pirmella 1/35, Nylia 1/35). Pharmacies typically carry only one or two, rotating based on wholesaler pricing, not patient prescriptions.

21-day format understock: The 21-day pack is significantly less prescribed than the 28-day format. Many pharmacies do not stock it routinely or order it only on demand, creating delays.

Insurance formulary shifts: Some PBMs have shifted preferred generic status away from Nortrel to lower-cost competitors, reducing pharmacy stocking incentives.

Clinical Profile of Nortrel 1/35 21 Day

Nortrel 1/35 is a monophasic combination oral contraceptive. Each active tablet contains:

Norethindrone 1 mg — a synthetic progestin with moderate androgenic activity. Suppresses LH and FSH; alters cervical mucus and endometrial receptivity.

Ethinyl estradiol 0.035 mg — a synthetic estrogen that suppresses FSH and stabilizes the endometrium to reduce breakthrough bleeding.

The 21-day regimen: 21 active tablets taken daily, followed by a 7-day hormone-free interval (HFI) during which withdrawal bleeding typically occurs. FDA-approved solely for contraception. Not indicated for emergency contraception.

Key Contraindications and Prescribing Considerations

Nortrel 1/35 21 Day carries the standard combination OCP contraindication profile, including:

Current or history of thromboembolic disorders (DVT, PE, cerebrovascular accident, coronary artery disease)

Smokers aged ≥35 years

Uncontrolled hypertension or hypertension with vascular disease

Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease

Hepatic dysfunction or hepatic neoplasia

Known or suspected pregnancy

Concurrent use of Hepatitis C drug combinations (ombitasvir/paritaprevir/ritonavir ± dasabuvir) due to risk of ALT elevations

Clinically Equivalent Alternatives for Access Issues

When your patient cannot access Nortrel 1/35 21 Day, the following strategies are recommended in order of clinical preference:

Prescribe by generic name. Write for norethindrone/ethinyl estradiol 1 mg/0.035 mg tablets with DAW-0 (allow substitution). This permits the pharmacy to dispense whichever equivalent generic they have in stock without requiring prior authorization.

Switch to 28-day format. Nortrel 1/35 28 Day, Alyacen 1/35, Dasetta 1/35, and other 28-day formulations use the same active tablets. The HFI is managed with placebo tablets rather than a pill-free week, which may actually improve adherence.

Consider therapeutic alternatives. If no NE/EE 1/35 equivalent is available, consider other monophasic COCs: norgestimate/EE 0.25 mg/0.035 mg (Sprintec class), or a lower-estrogen option such as norethindrone acetate/EE 1 mg/0.02 mg (Junel 1/20 class).

Consider LARC for patients with recurring access issues. For patients who repeatedly struggle to access their oral contraceptive, a long-acting reversible contraceptive (hormonal IUD, etonogestrel implant) may provide better continuous protection and eliminate refill burden.

Managing Continuity of Coverage

A lapse in oral contraceptive use — even a few days — can reduce cycle-level effectiveness and cause unpredictable bleeding. When a patient contacts your office with a supply issue:

Authorize the substitution promptly so the pharmacist can dispense an equivalent same-day.

Advise use of backup contraception (condoms) if ≥1 active dose has been missed.

If a full pack has been missed and the patient is sexually active, assess for pregnancy risk and consider EC counseling as appropriate.

How medfinder Helps Your Patients

medfinder is a service that calls pharmacies on behalf of patients to locate in-stock medications. When your patient can't find Nortrel 1/35 21 Day, directing them to medfinder.com/providers allows them to locate a pharmacy with the medication in stock without spending time on hold. Providers can recommend medfinder as a patient resource for any medication access challenge.

For more provider guidance, see our article: How to Help Your Patients Find Nortrel 1/35 21 Day In Stock: A Provider's Guide.